Get the Stockscreener App
9.31
0.21%
-0.02
After Hours:
9.30
-0.010
-0.11%
Poseida Therapeutics Inc Stock (PSTX) Latest News
Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric - MSN
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success - MSN
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet - MSN
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - MSN
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - MSN
Poseida Therapeutics (FRA:2RZ) Degree of Operating Leverage : -0.28 (As of Sep. 2024) - GuruFocus.com
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Pentwater Capital Management LP Increases Stake in Poseida Therapeutics Inc - GuruFocus.com
Poseida Therapeutics executive chairman sells stock for $278,100 By Investing.com - Investing.com Nigeria
Poseida Therapeutics executive chairman sells stock for $278,100 - Investing.com India
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of PSTX, ENLC, BRKH and MNTX - Longview News-Journal
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc.PSTX - Business Wire
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. from Malin Corporation PLC, Pentwater Capital Management and others for $1.5 billion. - Marketscreener.com
Roche to acquire US-based Poseida Therapeutics - MSN
Advantage Alpha Capital Partners LP Invests $285,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics, cell therapy maker, triples on Nasdaq after being acquired by Roche - Kursiv Media
Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald - Yahoo Finance
Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 billion deal - MSN
Poseida Therapeutics (NASDAQ:PSTX) Lowered to "Hold" Rating by Cantor Fitzgerald - MarketBeat
Roche to acquire cell therapy maker Poseida for up to $1.5bn - World Pharmaceutical Frontiers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, ZUO, MNTX on Behalf of Shareholders - GlobeNewswire Inc.
Roche makes takeover bid for Poseida Therapeutics Inc - European Biotechnology News
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc.PSTX - PR Newswire
Poseida Therapeutics shares skyrocket on acquisition from pharma-giant Roche - Mugglehead
Roche snaps up Poseida for $1.5B - BioWorld Online
Roche rewards Poseida’s shareholders with high premium in $1B takeout - BioCentury
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Roche In $1.5 Bn Deal To Buy Poseida Therapeutics - UrduPoint News
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities (PSTX) - Seeking Alpha
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B - MSN
Poseida Therapeutics (NASDAQ:PSTX) Stock Skyrockets on News of Roche Holdings Acquisition - TipRanks
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - MedCity News
Roche Buys Poseida for up to $1.5B, Leaning Into Off-the-Shelf CAR T - BioSpace
Roche to Acquire Poseida Therapeutics in $1.5B Deal - USA Herald
Why Poseida Therapeutics Stock Is Rising 228% - Barron's
Roche Softens TIGIT Blow With Poseida Buyout - Citeline
Roche to buy cell therapy developer Poseida for $1B - BioPharma Dive
Trending : Roche to Buy Poseida Therapeutics for Up to $1.5 Billion - Marketscreener.com
Roche to acquire Poseida Therapeutics - The Pharma Letter
Poseida Therapeutics (PSTX) Soars Over 223% on Roche Acquisition News - GuruFocus.com
HC Wainwright Reiterates "Neutral" Rating for Poseida Therapeutics (NASDAQ:PSTX) - MarketBeat
Roche in $1.5 bn deal to buy Poseida Therapeutics - Medical Xpress
Poseida Therapeutics stock hits 52-week high at $9.28 - Investing.com
Poseida Therapeutics stock hits 52-week high at $9.28 By Investing.com - Investing.com UK
Poseida shares surge on $1.5 billion Roche acquisition deal By Investing.com - Investing.com Canada
Poseida shares surge on $1.5 billion Roche acquisition deal - Investing.com
Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - The Bakersfield Californian
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Yahoo Finance
Poseida Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion - MSN
Roche to Acquire Poseida Therapeutics (PSTX) for $1.5 Billion - GuruFocus.com
Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 bln deal - PharmaLive
Roche expands into cell therapy with $1.5B Poseida purchase - Türkiye Today
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - The Bakersfield Californian
Roche expands cell therapy capabilities with $1.5bn Poseida acquisition - PMLiVE
Malin share price up in ‘excellent outcome’ after Roche acquires portfolio company Poseida - Business Post
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):